Adcock Ingram names new CEO. Adcock Ingram stock faces delisting plan

Adcock Ingram appointed Rhulani Nhlaniki as chief executive on August 1, 2026, while Adcock Ingram stock faces a proposed delisting plan. Business Explainer reported the appointment on September 6, 2026, identifying Nhlaniki as the successor to Andy Hall.

New CEO inherits ownership change

Nhlaniki joined Adcock Ingram from Pfizer after more than 25 years in South Africa, sub-Saharan Africa and international pharmaceutical markets. The leadership change comes while NATCO Pharma is pursuing a transaction to acquire every Adcock Ingram share not held by Bidvest under an agreement announced in July 2025.

The proposed transaction remains subject to regulatory and shareholder approvals, and completion would move Adcock Ingram from the Johannesburg Stock Exchange into private ownership with Bidvest retaining control, according to Business Explainer on September 6, 2026.

Profit growth outpaced revenue

Adcock Ingram generated revenue below ZAR 10.0 billion in the year to June 2026, a 0.50 percent decline from the prior year. Trading profit increased 9.40 percent to ZAR 1.3 billion, with every division recording profit growth, according to Investing.com in its report dated August 31, 2026.

The operating contrast is clear: average price realization reached 1.80 percent, volumes grew 0.90 percent and operating expenses increased 1.20 percent. The regulated single exit price increase was 1.47 percent, limiting the company's ability to offset cost pressure through medicine pricing.

Unregulated products matter more

Adcock Ingram is responding to that pricing constraint by expanding consumer and baby care categories, where prices are set commercially rather than through the regulated medicine mechanism. The group operates prescription, over-the-counter, consumer and hospital divisions across three South African production sites.

For investors, the key tension is the gap between operating execution and ownership uncertainty. Trading profit advanced while revenue contracted, but the proposed transaction could change the stock's listing status once the approval process is complete.

Ownership plan sets the next test

The proposed NATCO Pharma transaction and the August 1, 2026 CEO transition are the two dates shaping the current Adcock Ingram story. The company also retains joint venture interests in National Renal Care and Adcock Ingram India, with equity-accounted earnings of ZAR 172.5 million in fiscal 2025, up 20.70 percent from the prior year, according to Business Explainer.